Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Acorda Therapeutics, Inc. (ACOR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/28/2022 8-K/A Quarterly results
05/16/2022 8-K/A Quarterly results
03/18/2022 8-K/A Quarterly results
Docs: "Corrected Press Release Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results"
03/04/2022 8-K/A Quarterly results
05/31/2019 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/19/2018 8-K/A Cost Associated with Exit or Disposal Activities
10/07/2013 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Acorda Therapeutics Appoints Michael Rogers Chief Financial Officer; David Lawrence Named Chief of Business Operations"
07/27/2011 8-K/A Other Events, Financial Statements and Exhibits
Docs: "Statement"
06/21/2011 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/17/2011 8-K/A Quarterly results
Docs: "Acorda Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results - AMPYRA® 2010 Fourth Quarter Net Revenue of $52.3 Million; AMPYRA Full Year 2010 Net Revenue of $133.1 Million - Year-End 2010 Cash, Cash Equivalents and Short-Term Investments of $240 Million - Full Year 2011 AMPYRA Net Revenue Guidance of $205-$230 Million"
10/06/2006 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Securities Purchase Agreement, by and among Acorda Therapeutics, Inc. and the purchasers listed on Exhibit A thereto"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy